Loading
A phase 1/2 trial of DR-01 in peripheral T-cell lymphomas, run by Dren Bio, now recruiting.
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas is a phase 1/2 interventional study registered as NCT05475925 by Dren Bio, with 200 participants planned, started 2022-07-13 and due to reach its primary completion in 2026-12. Interventions recorded: DR-01.
Shares T-cell large granular lymphocytic leukaemia and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.